Group 1: Key Announcements - Xianggu Jichuang currently holds a 5.8018% stake in Hangju Technology, classified as a financial investment [1] - Meibang Co., Ltd. has seen a short-term continuous rise in stock price, indicating potential market sentiment overheating and irrational speculation risks [1] - Dazhu Laser plans to invest $150 million to establish an overseas operation center in Southeast Asia [1] - Fengfan Co., Ltd. won a bid for a project worth approximately 184 million yuan from the Southern Power Grid [1] - Jialian Biological intends to acquire controlling interest in Shizhi Yuan for 237 million yuan and expand into new business [1] - Jiaokong Technology forecasts a net profit of 156 million yuan for 2025, representing an 86.13% year-on-year increase [1] - Zhongshun Jierou plans to repurchase shares worth between 60 million and 120 million yuan [1] - Zhixin Precision's director Zhang Guojun plans to reduce his stake by no more than 1.8562% [1] - ST Renfu aims to raise 3 to 3.5 billion yuan through a private placement to its controlling shareholder,招商生科 [1] - Kaipu Cloud has terminated a significant asset restructuring [1] Group 2: Performance Highlights - Zhongke Shuguang expects a net profit of 2.113 billion yuan for 2025, a year-on-year increase of 10.54% [2] - Zhongwei Semiconductor reported a net profit of 285 million yuan for 2025, reflecting a 108.05% year-on-year growth [2] - Jiaokong Technology's net profit for 2025 is projected at 156 million yuan, up 86.13% year-on-year [2] - Sry New Materials anticipates a net profit of 154 million yuan for 2025, a 35.04% increase year-on-year [2] - Wens Foodstuff Group's net profit for 2025 is expected to be 5.235 billion yuan, down 43.59% year-on-year [2] Group 3: Equity Acquisitions - Changxin Bochuang plans to acquire a 93.8108% stake in Shanghai Honghui Guanglian Communication Technology [3] - Shenlian Biological intends to acquire controlling interest in Shizhi Yuan for 237 million yuan and expand into new business [3] - Tongwei Co., Ltd. plans to purchase 100% equity of Lihua Qingneng, with stock suspension [3] Group 4: Share Buybacks - Kaipu Cloud plans to repurchase shares worth between 50 million and 100 million yuan [3] - Zhongshun Jierou intends to repurchase shares worth between 60 million and 120 million yuan [3] - Yuanli Co., Ltd. plans to repurchase shares worth between 50 million and 60 million yuan [3] Group 5: Shareholding Changes - Conch Cement plans to increase its A-share holdings by 700 million to 1.4 billion yuan [3] - Fushi Holdings' Song Chunqing plans to reduce his stake by no more than 2% [3] - Zhixin Precision's director Zhang Guojun plans to reduce his stake by no more than 1.8562% [3] - Yashiguangdian's director Lin Xuefeng plans to reduce his stake by no more than 0.976% [3] Group 6: Other Developments - ST Renfu (rights protection) plans to raise 3 to 3.5 billion yuan through a private placement to its controlling shareholder [3] - ST Xiangxue (rights protection) received a decision to extend the pre-restructuring period [3] - Kaipu Cloud has terminated a significant asset restructuring [3]

Major Announcements - Light Media's film "Fast and Furious 3" has achieved a cumulative box office revenue of approximately 2.926 billion yuan, with the company's revenue from this film estimated between 43 million to 53 million yuan, which exceeds 50% of the company's audited consolidated financial statement revenue for the most recent fiscal year [1] - Dazhong Laser plans to invest 150 million USD to establish an overseas operation center in Southeast Asia to enhance service capabilities and meet international market demands [1] - Shunlian Bio intends to acquire controlling interest in Yanzhou Shizhi Source Biotechnology Co., Ltd. for 237 million yuan, aiming to fully develop its innovative drug business [2] - Shaoneng Co. signed a cooperation agreement with Yuancan Company for an independent energy storage power station project, with a total agreement amount of 22 million yuan [3] - China Tianying received investment approval for the expansion of its waste-to-energy project in Hanoi, with an investment amount of approximately 220 million USD [4] - Gansu Energy's 2 million kW wind power project has received approval from the local development and reform bureau [5] - Kexin Machinery obtained a production license for ultra-high pressure vessels [6] Financial Performance - Zhongwei Semiconductor reported a net profit of 285 million yuan for 2025, a year-on-year increase of 108.05%, with total revenue of 1.122 billion yuan, up 23.09% [9] - Weidao Nano reported a net profit of 213 million yuan for 2025, a year-on-year decrease of 6.12%, with total revenue of 2.632 billion yuan, down 2.52% [10] - Wens Foodstuff Group reported a net profit of 5.235 billion yuan for 2025, a year-on-year decrease of 43.59%, with total revenue of 103.884 billion yuan, down 1.67% [11] - SanSheng Guojian reported a net profit of 2.939 billion yuan for 2025, a year-on-year increase of 317.09%, with total revenue of 4.199 billion yuan, up 251.81% [12] - Yongxi Electronics reported a net profit of 82.24 million yuan for 2025, a year-on-year increase of 23.99%, with total revenue of 4.4 billion yuan, up 21.92% [14] - YaoMai Technology reported a net profit of 137 million yuan for 2025, a year-on-year increase of 42.63%, with total revenue of 619 million yuan, up 24.33% [15] - Zhongke Shuguang reported a net profit of 2.113 billion yuan for 2025, a year-on-year increase of 10.54%, with total revenue of 14.97 billion yuan, up 13.86% [15] Shareholder Actions - Zhongshun Jierou plans to repurchase shares worth between 60 million to 120 million yuan for employee stock ownership plans [21] - Yuanli Co. plans to repurchase shares worth between 50 million to 60 million yuan for stock incentive plans [21] - Huaneng Hydropower's controlling shareholder plans to increase its stake by 100 million to 150 million yuan [22] - Conch Cement's controlling shareholder plans to increase its stake by 700 million to 1.4 billion yuan [23] Stock Suspension - Dongyangguang announced a stock suspension due to plans to acquire control of Dongshu No. 1 [29] - Tongwei Co. announced a stock suspension due to plans to acquire 100% equity of Qinghai Lihua Qingneng [30] - Duorui Pharmaceutical announced a stock suspension as the offer period for its acquisition has expired [31]

Core Viewpoint - The company, Shenlian Bio, plans to acquire a controlling stake in Yangzhou Shizhiyuan Biotechnology Co., Ltd. for 237 million yuan, aiming to enhance its innovative drug business and establish a dual-main business model of "human pharmaceuticals" and "animal health" [1] Group 1 - Shenlian Bio will use 237 million yuan of its own and self-raised funds, including bank acquisition loans, for the acquisition [1] - The acquisition will be executed through its wholly-owned subsidiary, Shanghai Bentianc Bio-pharmaceutical Co., Ltd. [1] - After the transaction, Bentianc and its concerted parties will hold a total of 51% equity in Shizhiyuan, allowing the company to control 51% of the voting rights [1]

Group 1: Key Developments in Technology and Innovation - Elon Musk envisions launching AI satellites from the Moon using electromagnetic catapults to create a satellite network for data centers [4] - Xiaomi plans to focus on core technologies such as chips, AI, and operating systems over the next five years to become a global tech leader [3] - Apple intends to purchase over 100 million advanced chips from TSMC's Arizona factory by 2026 [5] Group 2: Investment and Financial Performance - Hubei province is increasing investments in emerging industries like integrated circuits and embodied intelligence while optimizing real estate investments to boost domestic demand [2] - AMD has agreed to sell AI chips worth up to $60 billion to Meta, which will deploy 6 GW of AMD GPUs [6] - Zhongwei Semiconductor reported a net profit of 285 million yuan for 2025, a year-on-year increase of 108.05% [9] - Sry New Materials achieved a net profit of 154 million yuan in 2025, reflecting a 35.04% year-on-year growth [12] - Sanofi Guojian reported a net profit of 2.939 billion yuan for 2025, a staggering increase of 317.09% [12] Group 3: Corporate Actions and Strategic Moves - Shenlian Bio plans to acquire a controlling stake in Shizhi Yuan for 237 million yuan to expand into innovative pharmaceuticals [8] - Kaipu Cloud terminated its acquisition of Nanning Taike due to market changes and lack of agreement on key terms [8] - Senno Medical's subsidiary received EU CE MDR certification for its Ghunter intracranial thrombectomy stent, enabling entry into the EU market [14] Group 4: Financing and Market Activity - Qianxun Intelligent completed nearly 2 billion yuan in financing, with a valuation exceeding 10 billion yuan [15] - Renxin Technology, a leader in high-speed automotive SerDes chips, completed a strategic round of financing led by SAIC and other industry capital [16]

证券代码：688098 证券简称：申联生物 公告编号：2026-005 申联生物医药(上海)股份有限公司 关于收购联营公司控股权并开展新业务 暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司拟使用23,744.1789万元的自有资金及自筹资金（包括银行并购贷款 ），通过全资子公司上海本天成生物医药有限公司（以下简称"本天成"）以股权 转让及增资的方式取得联营公司扬州世之源生物科技有限责任公司（以下简称" 世之源"或"目标公司"）的控股权，本次交易完成后本天成持有世之源的股权由 16.99%增加到40.65%，本天成的一致行动人上海申源启航企业管理合伙企业（ 有限合伙）（以下简称"上海申源启航"或"员工持股平台"）投资7,995.6392万元 取得世之源新增的10.35%股权，因此本天成及一致行动人将合计持有世之源 51.00%的股权，公司能够控制世之源51%股权的表决权，世之源成为公司的控股 孙公司，纳入上市公司合并报表范围。 本次收购完成后，公司将全面开展创新药业务，形成"人用药品"与" ...

Group 1 - Hengyu Environmental reported a revenue of 294 million yuan for 2025, an increase of 89.87%, and a net profit of 35.93 million yuan, up 106.25% year-on-year [1] - Yongxi Electronics achieved a revenue of 4.4 billion yuan in 2025, a growth of 21.92%, with a net profit of 82.24 million yuan, reflecting a year-on-year increase of 23.99% [2] - Zhongwei Semiconductor reported a revenue of 1.122 billion yuan for 2025, a 23.09% increase, and a net profit of 285 million yuan, up 108.05% year-on-year [3] - Sry New Materials achieved a revenue of 1.564 billion yuan in 2025, a growth of 17.66%, with a net profit of 154 million yuan, reflecting a year-on-year increase of 35.04% [14] - Jiaokong Technology reported a revenue of 2.537 billion yuan for 2025, a growth of 16.08%, and a net profit of 156 million yuan, up 86.13% year-on-year [15] - SanSheng Guojian reported a revenue of 4.199 billion yuan for 2025, a significant increase of 251.81%, with a net profit of 2.939 billion yuan, up 317.09% year-on-year [30] Group 2 - Aidi Pharmaceutical reported a revenue of 721 million yuan for 2025, a growth of 72.49%, but incurred a net loss of 19.73 million yuan, reducing losses from 142 million yuan in the previous year [5] - Weidao Nano reported a revenue of 2.632 billion yuan for 2025, a decrease of 2.52%, with a net profit of 213 million yuan, down 6.12% year-on-year [9] - Wens Foodstuff Group reported a revenue of 103.884 billion yuan for 2025, a decline of 1.67%, with a net profit of 5.235 billion yuan, down 43.59% year-on-year [29] - Supor reported a revenue of 22.772 billion yuan for 2025, a growth of 1.54%, with a net profit of 2.097 billion yuan, down 6.58% year-on-year [33] Group 3 - ShaoNeng Co. signed a significant operational contract worth 22 million yuan for a biomass power generation project [6] - Shunlian Bio plans to use 237 million yuan to acquire controlling interest in a joint venture, increasing its stake from 16.99% to 51% [7] - Huason Pharmaceutical's subsidiary received clinical trial approval for an innovative drug, indicating progress in its product pipeline [8] - Xinyang Technology's subsidiary received a medical device registration certificate, enhancing its product offerings [10][11] - Yida Co. obtained an investment project filing certificate for a chemical production project with a total investment of 642 million yuan [12]

证券代码：688098 证券简称：申联生物 公告编号：2026-006 申联生物医药(上海)股份有限公司 关于召开2026年第一次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 （一） 股东会类型和届次 2026年第一次临时股东会 （二） 股东会召集人：董事会 （三） 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相 结合的方式 （四） 现场会议召开的日期、时间和地点 重要内容提示： 股东会召开日期：2026年3月12日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 一、 召开会议的基本情况 网络投票起止时间：自2026 年 3 月 12 日 至2026 年 3 月 12 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互联 网投票平台的投票时间为股东会召开当日的 9:15-15:00。 （六） 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉 ...

申联生物医药（上海）股份有限公司 2026 年第一次临时股东会会议资料 证券代码：688098 证券简称：申联生物 申联生物医药（上海）股份有限公司 2026 年第一次临时股东会会议资料 2026 年 3 月 1 申联生物医药（上海）股份有限公司 2026 年第一次临时股东会会议资料 目录 | 申联生物医药（上海）股份有限公司 | 2026 | 年第一次临时股东会会议须知 3 | | --- | --- | --- | | 申联生物医药（上海）股份有限公司 | 2026 | 年第一次临时股东会会议议程 5 | | 申联生物医药（上海）股份有限公司 | 2026 | 年第一次临时股东会会议议案 7 | | 议案 1：关于续聘会计师事务所的议案 | | 7 | 议案 2：关于收购联营公司控股权并开展新业务暨关联交易的议案 ..... 10 2 申联生物医药（上海）股份有限公司 2026 年第一次临时股东会会议资料 申联生物医药（上海）股份有限公司 2026 年第一次临时股东会会议须知 为了维护申联生物医药（上海）股份有限公司（以下简称"公司"）全体股 东的合法权益，确保股东会的正常秩序和议事效率，保证会议的顺利进 ...

格隆汇2月24日丨申联生物(688098.SH)公布，公司拟使用23,744.1789万元的自有资金及自筹资金（包括 银行并购贷款），通过全资子公司本天成以股权转让及增资的方式取得联营公司世之源的控股权。其 中，本天成拟支付3,144.1789万元受让摩尼肽（上海）生物科技有限公司（以下简称"摩尼肽"）持有的 世之源1,532.7024万元的注册资本；本天成拟出资20,600万元认购世之源新增注册资本10,041.9445万 元，以上股权转让及增资完成后，本天成将持有世之源40.65%的股权。 同时，由世之源新设的员工持股平台上海申源启航出资7,995.6392万元认购世之源新增注册资本 3,897.6585万元，取得世之源新增的10.35%股权；且上海申源启航与本天成签署一致行动协议，上海申 源启航为本天成的一致行动人；同时上海万舟行企业管理合伙企业（有限合伙）（以下简称"上海万舟 行"）出资3,592.2437万元对世之源进行增资，取得世之源新增的4.65%股权。以上增资及股权转让完成 后，本天成及其一致行动人合计持有世之源51.00%的股权，公司能够控制世之源51%的表决权，世之源 成为公司的控股孙公司 ...

Core Viewpoint - The company plans to acquire a controlling stake in Yangzhou Shizhiyuan Biotechnology Co., Ltd. through its wholly-owned subsidiary, Shanghai Bentianc Biopharmaceutical Co., Ltd., using 237 million yuan of its own and raised funds [1] Group 1: Acquisition Details - The company will hold 51% of the equity in Shizhiyuan after the transaction, making it a controlled subsidiary [1] - The acquisition will be executed through equity transfer and capital increase [1] Group 2: Business Strategy - Following the completion of the acquisition, the company will fully develop its innovative drug business [1] - The company aims to establish a new pattern of dual main businesses, focusing on "human pharmaceuticals" and "animal health" [1]